➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
McKinsey
Moodys
Mallinckrodt

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENZOYLECGONINE


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Benzoylecgonine

Trial ID Title Status Sponsor Phase Summary
NCT00015067 ↗ Cocaine-Methylphendidate Interaction Study - 4 Completed Cincinnati MDRU Phase 1 The purpose of this study is to attempt to identify possible dangerous interactions between cocaine and methylphenidate (MPD). Additional objectives are to determine: a) if MPD reduces the craving and high for cocaine; b) if there are pharmacokinetic and pharmacodynamic interactions between cocaine and MPD; and c) the relationship between cocaine and benzoylecgonine (BE) levels in plasma and BE levels in urine.
NCT00015067 ↗ Cocaine-Methylphendidate Interaction Study - 4 Completed National Institute on Drug Abuse (NIDA) Phase 1 The purpose of this study is to attempt to identify possible dangerous interactions between cocaine and methylphenidate (MPD). Additional objectives are to determine: a) if MPD reduces the craving and high for cocaine; b) if there are pharmacokinetic and pharmacodynamic interactions between cocaine and MPD; and c) the relationship between cocaine and benzoylecgonine (BE) levels in plasma and BE levels in urine.
NCT00015080 ↗ Naltrexone in Treatment of Cocaine Dependence - 5 Completed Cincinnati MDRU Phase 2 The purpose of this study is to determine the efficacy of naltrexone in the treatment of cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2) decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in treatment.
NCT00015080 ↗ Naltrexone in Treatment of Cocaine Dependence - 5 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine the efficacy of naltrexone in the treatment of cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2) decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in treatment.
NCT00032929 ↗ Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed Somerset Pharmaceuticals Phase 3 The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.
NCT00032929 ↗ Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed National Institute on Drug Abuse (NIDA) Phase 3 The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.
NCT00086255 ↗ Tiagabine for the Treatment of Cocaine Dependence - 1 Completed University of Cincinnati Phase 2 The purpose of this study is to assess tiagabine for the treatment of cocaine dependence.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Benzoylecgonine

Condition Name

Condition Name for
Intervention Trials
Cocaine Dependence 10
Cocaine-Related Disorders 5
Adult Attention Deficit Hyperactivity Disorder 1
Cocaine Use Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Cocaine-Related Disorders 16
Attention Deficit Disorder with Hyperactivity 1
Impulsive Behavior 1
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Benzoylecgonine

Trials by Country

Trials by Country for
Location Trials
United States 30
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Pennsylvania 5
Ohio 5
Texas 4
Maryland 3
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Benzoylecgonine

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 1
Phase 2 10
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 14
Withdrawn 2
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Benzoylecgonine

Sponsor Name

Sponsor Name for
Sponsor Trials
National Institute on Drug Abuse (NIDA) 13
University of Pennsylvania 5
Cincinnati MDRU 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 18
NIH 13
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.